CD33 and non-small cell lung carcinoma: However, there were increases in myeloid populations in stage I-IVA NSCLC patients after treatment onset, with an increase in the CD33+ myeloid population overall (p=0.0058; Figure 1C), particularly the CD33+ CD14- population (p=0.024; Figures 1C–F).